1644 related articles for article (PubMed ID: 12539223)
1. Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models.
Denmeade SR; Sokoll LJ; Dalrymple S; Rosen DM; Gady AM; Bruzek D; Ricklis RM; Isaacs JT
Prostate; 2003 Mar; 54(4):249-57. PubMed ID: 12539223
[TBL] [Abstract][Full Text] [Related]
2. Docetaxel down-regulates the expression of androgen receptor and prostate-specific antigen but not prostate-specific membrane antigen in prostate cancer cell lines: implications for PSA surrogacy.
Kuroda K; Liu H; Kim S; Guo M; Navarro V; Bander NH
Prostate; 2009 Oct; 69(14):1579-85. PubMed ID: 19575420
[TBL] [Abstract][Full Text] [Related]
3. A novel regulation of PSMA and PSA expression by Q640X AR in 22Rv1 and LNCaP prostate cancer cells.
Ben Jemaa A; Sallami S; Céraline J; Oueslati R
Cell Biol Int; 2013 May; 37(5):464-70. PubMed ID: 23418075
[TBL] [Abstract][Full Text] [Related]
4. Alterations of prostate biomarker expression and testosterone utilization in human LNCaP prostatic carcinoma cells by garlic-derived S-allylmercaptocysteine.
Pinto JT; Qiao C; Xing J; Suffoletto BP; Schubert KB; Rivlin RS; Huryk RF; Bacich DJ; Heston WD
Prostate; 2000 Dec; 45(4):304-14. PubMed ID: 11102955
[TBL] [Abstract][Full Text] [Related]
5. Secretion of endogenous kallikreins 2 and 3 by androgen receptor-transfected PC-3 prostate cancer cells.
Kollara A; Diamandis EP; Brown TJ
J Steroid Biochem Mol Biol; 2003 Apr; 84(5):493-502. PubMed ID: 12767274
[TBL] [Abstract][Full Text] [Related]
6. Enhanced androgen receptor signaling correlates with the androgen-refractory growth in a newly established MDA PCa 2b-hr human prostate cancer cell subline.
Hara T; Nakamura K; Araki H; Kusaka M; Yamaoka M
Cancer Res; 2003 Sep; 63(17):5622-8. PubMed ID: 14500404
[TBL] [Abstract][Full Text] [Related]
7. Suramin-induced decrease in prostate-specific antigen expression with no effect on tumor growth in the LNCaP model of human prostate cancer.
Thalmann GN; Sikes RA; Chang SM; Johnston DA; von Eschenbach AC; Chung LW
J Natl Cancer Inst; 1996 Jun; 88(12):794-801. PubMed ID: 8637045
[TBL] [Abstract][Full Text] [Related]
8. Derivation of androgen-independent human LNCaP prostatic cancer cell sublines: role of bone stromal cells.
Wu HC; Hsieh JT; Gleave ME; Brown NM; Pathak S; Chung LW
Int J Cancer; 1994 May; 57(3):406-12. PubMed ID: 8169003
[TBL] [Abstract][Full Text] [Related]
9. Serum prostate specific antigen levels in mice bearing human prostate LNCaP tumors are determined by tumor volume and endocrine and growth factors.
Gleave ME; Hsieh JT; Wu HC; von Eschenbach AC; Chung LW
Cancer Res; 1992 Mar; 52(6):1598-605. PubMed ID: 1371718
[TBL] [Abstract][Full Text] [Related]
10. Interactive effects of triiodothyronine and androgens on prostate cell growth and gene expression.
Zhang S; Hsieh ML; Zhu W; Klee GG; Tindall DJ; Young CY
Endocrinology; 1999 Apr; 140(4):1665-71. PubMed ID: 10098501
[TBL] [Abstract][Full Text] [Related]
11. Prostate-specific antigen (PSA) promoter-driven androgen-inducible expression of sodium iodide symporter in prostate cancer cell lines.
Spitzweg C; Zhang S; Bergert ER; Castro MR; McIver B; Heufelder AE; Tindall DJ; Young CY; Morris JC
Cancer Res; 1999 May; 59(9):2136-41. PubMed ID: 10232600
[TBL] [Abstract][Full Text] [Related]
12. Establishment and characterization of androgen-independent human prostate cancer cell lines, LN-REC4 and LNCaP-SF, from LNCaP.
Iwasa Y; Mizokami A; Miwa S; Koshida K; Namiki M
Int J Urol; 2007 Mar; 14(3):233-9. PubMed ID: 17430262
[TBL] [Abstract][Full Text] [Related]
13. Different proportions of various prostate-specific antigen (PSA) and human kallikrein 2 (hK2) forms are present in noninduced and androgen-induced LNCaP cells.
Kumar A; Mikolajczyk SD; Hill TM; Millar LS; Saedi MS
Prostate; 2000 Aug; 44(3):248-54. PubMed ID: 10906742
[TBL] [Abstract][Full Text] [Related]
14. 1alpha,25-dihydroxyvitamin D3 inhibits prostate cancer cell growth by androgen-dependent and androgen-independent mechanisms.
Zhao XY; Peehl DM; Navone NM; Feldman D
Endocrinology; 2000 Jul; 141(7):2548-56. PubMed ID: 10875257
[TBL] [Abstract][Full Text] [Related]
15. p,p'-Dichlorodiphenyltrichloroethane (p,p'-DDT) and p,p'-dichlorodiphenyldichloroethylene (p,p'-DDE) repress prostate specific antigen levels in human prostate cancer cell lines.
Wong LI; Labrecque MP; Ibuki N; Cox ME; Elliott JE; Beischlag TV
Chem Biol Interact; 2015 Mar; 230():40-9. PubMed ID: 25682698
[TBL] [Abstract][Full Text] [Related]
16. Two mutations identified in the androgen receptor of the new human prostate cancer cell line MDA PCa 2a.
Zhao XY; Boyle B; Krishnan AV; Navone NM; Peehl DM; Feldman D
J Urol; 1999 Dec; 162(6):2192-9. PubMed ID: 10569618
[TBL] [Abstract][Full Text] [Related]
17. Butyrate analogue, isobutyramide, inhibits tumor growth and time to androgen-independent progression in the human prostate LNCaP tumor model.
Gleave ME; Sato N; Sadar M; Yago V; Bruchovsky N; Sullivan L
J Cell Biochem; 1998 Jun; 69(3):271-81. PubMed ID: 9581866
[TBL] [Abstract][Full Text] [Related]
18. Prostate-specific suicide gene therapy using the prostate-specific membrane antigen promoter and enhancer.
O'Keefe DS; Uchida A; Bacich DJ; Watt FB; Martorana A; Molloy PL; Heston WD
Prostate; 2000 Oct; 45(2):149-57. PubMed ID: 11027414
[TBL] [Abstract][Full Text] [Related]
19. LNCaP progression model of human prostate cancer: androgen-independence and osseous metastasis.
Thalmann GN; Sikes RA; Wu TT; Degeorges A; Chang SM; Ozen M; Pathak S; Chung LW
Prostate; 2000 Jul; 44(2):91-103 Jul 1;44(2). PubMed ID: 10881018
[TBL] [Abstract][Full Text] [Related]
20. Robust prostate-specific expression for targeted gene therapy based on the human kallikrein 2 promoter.
Xie X; Zhao X; Liu Y; Young CY; Tindall DJ; Slawin KM; Spencer DM
Hum Gene Ther; 2001 Mar; 12(5):549-61. PubMed ID: 11268287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
